ナイジェリアの薬局から供給される薬剤の製薬簿の品質
R B Taylor1, O Shakoor, R H Behrens
1School of Pharmacy, The Robert Gordon University, Schoolhill, AB10 1FR, Aberdeen, UK.
Lancet (London, England)
|June 27, 2001
まとめ
ナイジェリアの薬局にある医薬品のほぼ半分は,有効成分レベルが大きく異なる品質テストに失敗しました. 製造品質保証の不良が原因であり,治療の失敗や抗菌剤耐性につながる可能性がある.
科学分野:
- 医薬品科学 医薬品科学とは
- 薬用化学 薬用化学について
- 公衆衛生は公衆衛生である.
背景:
- 劣った医薬品は,偽造,分解,劣悪な製造により,開発途上国において重大な脅威となっている.
- 医薬品の有効成分が不十分である場合,治療が失敗し,薬剤耐性が生じることがあります.
研究 の 目的:
- ナイジェリアの小売薬局で入手可能な様々な薬物の品質を調査する.
- 薬剤の質が悪い原因を特定し,有効成分含有量を含む.
主な方法:
- ナイジェリアのラゴスとアブジャの35の薬局から27種類の薬剤で581の薬剤サンプルをランダムに採取した.
- 薬物の含有量の分析は,検証されたクロマトグラフィ法を用いて行われます.
- 分析された薬物含有量を,既定の製薬書標準と比較する.
主要な成果:
- 薬物のサンプルのうち48% (581件中279件) は,有効成分含有量の製薬簿の制限値を満たしていない.
- 変化には,有効成分のないサンプル,および許容範囲を超えた量または許容範囲未満の量を含むものが含まれています.
- 不服従率は,さまざまな薬物カテゴリーで一貫していました.
結論:
- 製薬製造中の不十分な品質保証は,標準以下の医薬品の主要な原因です.
- 発展途上国における低品質の医薬品の普及は,世界的な抗菌剤耐性および感染症に対する治療の失敗に寄与しています.
関連する概念動画
Drug Nomenclature
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Drug Product Stability
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...


